In summary, AMPK has the ability to reduce the immunosuppression of TIME and improve the effectiveness of tumor immunotherapy by regulating the metabolism and activity of T cells, B cells, NK cells, macrophages, and other immune cells of TIME. This evidence concerns the gene PRKAA1 and neoplasm.